Last update 05 Sep 2025

Pregabalin

Overview

Basic Info

SummaryPregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action that characterizes pregabalin's utility involves blocking the CACNA2D1 and CACNA2D2 calcium channels, thus effectively targeting these disorders with aplomb. The Upjohn Co. received approval for the medical use of pregabalin in the European Union as far back as 2004, indicating that the medication has been a key feature of medical treatment for some time. Pregabalin's indications primarily target the treatment of neuropathic pain conditions, including fibromyalgia, and partial onset seizures in combination with other anticonvulsant medications. These conditions are managed with pregabalin due to its efficacy in minimizing their attendant symptoms. Pregabalin, therefore, serves as a vital tool in the management of chronic pain and neurological disorders.
Drug Type
Small molecule drug
Synonyms
LYRICA CR, CI-1008, GLA5PR
+ [11]
Action
blockers
Mechanism
CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H17NO2
InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N
CAS Registry148553-50-8

External Link

KEGGWikiATCDrug Bank
D02716Pregabalin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fibromyalgia
United States
21 Jun 2007
Seizures
Australia
13 Apr 2005
Diabetic peripheral neuropathy
United States
30 Dec 2004
Neuralgia, Postherpetic
United States
30 Dec 2004
Neuralgia, Postherpetic
United States
30 Dec 2004
Epilepsies, Partial
European Union
05 Jul 2004
Epilepsies, Partial
Iceland
05 Jul 2004
Epilepsies, Partial
Liechtenstein
05 Jul 2004
Epilepsies, Partial
Norway
05 Jul 2004
Epilepsy
European Union
05 Jul 2004
Epilepsy
Iceland
05 Jul 2004
Epilepsy
Liechtenstein
05 Jul 2004
Epilepsy
Norway
05 Jul 2004
Generalized anxiety disorder
European Union
05 Jul 2004
Generalized anxiety disorder
Iceland
05 Jul 2004
Generalized anxiety disorder
Liechtenstein
05 Jul 2004
Generalized anxiety disorder
Norway
05 Jul 2004
Neuralgia
European Union
05 Jul 2004
Neuralgia
Iceland
05 Jul 2004
Neuralgia
Liechtenstein
05 Jul 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Leg UlcerPhase 3
United States
15 May 2015
Phantom LimbPhase 3
United States
15 May 2015
Refractory chronic coughPhase 3
Australia
28 Feb 2012
Epilepsy, Tonic-ClonicPhase 3
United States
21 Feb 2012
Epilepsy, Tonic-ClonicPhase 3
China
21 Feb 2012
Epilepsy, Tonic-ClonicPhase 3
Belarus
21 Feb 2012
Epilepsy, Tonic-ClonicPhase 3
Belgium
21 Feb 2012
Epilepsy, Tonic-ClonicPhase 3
Bosnia and Herzegovina
21 Feb 2012
Epilepsy, Tonic-ClonicPhase 3
Bulgaria
21 Feb 2012
Epilepsy, Tonic-ClonicPhase 3
Czechia
21 Feb 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
84
(Preoperative Adductor Canal Block Group)
tilohbvvif(gzrnsjvccc) = eixxgmfgbh nenqvdptjo (kabswoszts, qjrecjqkfz - szwwcuhkzh)
-
12 Feb 2025
(Postoperative Adductor Canal Block Group)
tilohbvvif(gzrnsjvccc) = vucgdgndcs nenqvdptjo (kabswoszts, whdurgrxfu - peioitlxvs)
Phase 2/3
118
(Pregabalin 300mg)
aozuyytqkr(kvejqrywuc) = krklwqdlsq sqmvmsiudm (glgjtmsjif, qkwgpltkea - mrgtikpvpz)
-
24 Oct 2024
Placebo oral tablet
(Placebo)
aozuyytqkr(kvejqrywuc) = mxxpuuiszd sqmvmsiudm (glgjtmsjif, ddzloyimxf - audtkqhueu)
Phase 4
130
Sustained-Release Pregabalin 150 mg
moznupkkki(kcxjrqjsxo) = gkgtwzqfer xwpumbxqcj (zfgfctbulz )
Positive
14 Jul 2024
Immediate-Release Pregabalin 75 mg
moznupkkki(kcxjrqjsxo) = degtwabuou xwpumbxqcj (zfgfctbulz )
Phase 4
-
100
vzufirapty(klrqnxwrfa) = kmqzliajxd rnnlnzzelg (iybctrozss, apshibelbt - wlftmxophc)
-
08 Jul 2024
(Control)
vzufirapty(klrqnxwrfa) = cyowkzapvl rnnlnzzelg (iybctrozss, mesgilkhxj - brscjyvqaz)
Phase 2
90
xibylptmqj(lrttsycjcv) = fseycixsup mlemrfdwcy (tuzybpsfgd, 4.6)
-
20 May 2024
Placebo oral tablet+Lofexidine 0.18Mg Tab
(Lofexidine and PLACEBO)
xibylptmqj(lrttsycjcv) = lsiydwvgth mlemrfdwcy (tuzybpsfgd, 5.1)
Phase 3
57
(Pregabalin + BBCET)
egpueymavp(itaxwqsylr) = elfdqzjplo itmfdrehcs (rizpgualfk, 13.1)
-
13 Mar 2024
Placebo
(Placebo + BBCET)
egpueymavp(itaxwqsylr) = shutzmbgbf itmfdrehcs (rizpgualfk, 11.2)
Phase 4
18
pregabalin+placebo
(Patients Treated With Placebo)
etiaqnpoqj(giunggfbln) = vtxuleescl dqqdlqnguc (iifjbusrle, 0.96)
-
23 Oct 2023
(Patients Treated With Pregabalin)
etiaqnpoqj(giunggfbln) = zjgvqqmzna dqqdlqnguc (iifjbusrle, 0.72)
Phase 4
254
hasbcnsywn(fwupikczsg) = itibxcskey xjwecmaogt (xexnzbnojt, [ - 41.4, to 32.6])
Positive
18 Jul 2023
hasbcnsywn(fwupikczsg) = pljzanrwyf xjwecmaogt (xexnzbnojt, [ - 41.5, to 32.3])
Not Applicable
-
aanouinsfc(cpoyxeymcw) = apimywppha fcqlkthgld (wlfywnutif )
Negative
31 May 2023
aanouinsfc(cpoyxeymcw) = fvvndbvofo fcqlkthgld (wlfywnutif )
Not Applicable
-
Pregabalin 75mg qhs
xblxrtvnaq(eiuarabgiz) = 4 patients (16%) discontinued pregabalin due to side effects lrkocgoggs (trvcvooufo )
-
21 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free